Abstract
Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the preferred approach to the management of adults with UC and represent the official practice recommendations of the American College of Gastroenterology. The scientific evidence for these guidelines was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) process. In instances where the evidence was not appropriate for GRADE, but there was consensus of significant clinical merit, "key concept" statements were developed using expert consensus. These guidelines are meant to be broadly applicable and should be viewed as the preferred, but not only, approach to clinical scenarios.
MeSH terms
-
Adalimumab / therapeutic use
-
Anti-Inflammatory Agents / therapeutic use*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Biopsy*
-
Budesonide / therapeutic use
-
Colitis, Ulcerative / diagnosis*
-
Colitis, Ulcerative / pathology
-
Colitis, Ulcerative / therapy*
-
Colonoscopy*
-
Colorectal Neoplasms / prevention & control*
-
Disease Management
-
Early Detection of Cancer
-
Gastroenterology
-
Gastrointestinal Agents / therapeutic use*
-
Humans
-
Infliximab / therapeutic use
-
Maintenance Chemotherapy
-
Mesalamine / therapeutic use
-
Prognosis
-
Remission Induction
-
Severity of Illness Index
-
Societies, Medical
-
Tumor Necrosis Factor-alpha / antagonists & inhibitors
Substances
-
Anti-Inflammatory Agents
-
Anti-Inflammatory Agents, Non-Steroidal
-
Gastrointestinal Agents
-
Tumor Necrosis Factor-alpha
-
Mesalamine
-
Budesonide
-
Infliximab
-
Adalimumab